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ABSTRACT
Introduction: Renal cell carcinoma (RCC) is the most common renal malignancies. In advanced stage, it is highly 
resistant to systemic therapies. RCC is a highly vascular tumour and angiogenesis pathway has been postulated in its 
carcinogenesis. Novel drug targeting Vascular Endothelial Growth Factor (VEGF) and advanced surgical interven-
tions have shown to increase the overall patients’ survival. In this study, we evaluated the VEGF expression of RCC 
using immunohistochemistry technique and its potential correlation with the tumour grades. Methods: 40 RCC cases 
that underwent nephrectomy were selected. The archived samples of formalin fixed, paraffin-embedded (FFPE) were 
retrieved. The tumour tissue blocks were carefully chosen, sectioned and stained with VEGF using immunohisto-
chemistry technique. The intensity of VEGF expression was scored as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ 
(strong).  Results: Majority of the RCC cases were male, with male to female ratio of 2.1:1. Mean patient age was 
56.2 years (age ranged between 16 to 74 years).  Most of the cases were Malays (42.5 %). VEGF was expressed in 
36 (90%) of RCC cases. Among the 36 cases that were immunopositive, 8 (16.7%) were grade 1, 20 (55.6%) grade 
2 and 8 (16.7%) grade 3.  There was no significant association between VEGF expressions score and grades of RCC 
(p=0.39). Conclusion: VEGF was expressed in majority of RCC cases although there was no significant association 
with tumour grades.
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Renal cancer is the 13th most common malignancy 
globally, and has increased by 2% annually during 
the last two decades (1). RCC or previously known 
as hypernephroma accounts for 90% of all renal 
malignancies. In the United States, RCC represented 
5% of all cancers in men and 3% of all cancers in 
women in 2013. It is a cancer of adult and most often 
occurs between the sixth and seventh decades of life. 
The incidence of RCC is 1.6 to 2.0 times higher in men 
than in women; men account for almost two thirds of all 
deaths (2, 3).  In Malaysia, RCC accounts for 43.8% of 
all renal cancer. The incidence is higher in men (1.7%) 
than in women (0.6%). It is most commonly found in 
Chinese followed by Malays and Indian (4).
RCC originates from renal tubular epithelium and has a 
wide variation of histopathological patterns. Three major 
types of RCC are clear cell carcinoma, papillary RCC 
and chromophobe RCC. The most common type is clear 
cell carcinoma, which accounts for 80% of all RCCs 
(5). RCC has unpredictable behaviour and its mortality 
rate is higher than other urological malignancies.  It 
can metastasize to other organs such as lung, liver and 
adrenal gland (6). Approximately only 50-60% of RCC is 
localized and can be cured by surgical treatment.  
RCC is a highly vascular solid tumour and acquires 
nutrients for survival by forming new blood vessels 
(neovascularization) or sprouting new blood vessels from 
old existing vessels (angiogenesis) (7, 8). Angiogenesis is 
the prime event to the onset of early tumorigenesis and 
it is found to be regulated by a number of angiogenic 
factors (9). One such factor is vascular endothelial 
growth factor (VEGF). Its angiogenic capability allows 
the tumour advancement and metastasis hence increases 
the grade and stage of the tumour.
VEGF is a dimeric 46-Kd, endothelial cell specific, 
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glycosylated, and heparin-binding cytokine. It is 
synthesized by both normal and tumour cells and acts 
specifically on endothelial cells by stimulating vascular 
endothelial growth (10). It is potent and has high specific 
angiogenic factor that is capable of stimulating tumour 
growth through its autocrine property. It also exerts 
paracrine effects by binding to specific tyrosine kinase-
receptors on vascular endothelial cells and has vascular 
permeability factor functions that promote metastasis 
(11, 12).
Several studies have found significant differences 
in serum VEGF level between normal and RCC and 
significant correlations between serum VEGF levels with 
tumour volume. These findings showed that circulating 
VEGF has a potential as a biomarker for RCC (13, 14). 
Nevertheless, despite the significant correlation between 
serum VEGF levels with tumour volume, correlation 
between VEGF serum levels and tumour stage, patients’ 
survival, or tumour metastasis were still unable to be 
determined (15). Serum VEGF level has limited value as 
a tumour marker; hence FFPE of RCC cases were used in 
this study (15-17)
In this study, we examined the VEGF protein expression 
in FFPE RCC samples from nephrectomy specimen 
using immunohistochemistry technique. The correlation 




This cross sectional study was conducted by retrieving 
RCC cases diagnosed within five years from the 
departmental archive. Cases of missing blocks or 
incomplete blocks were excluded. This study was 
approved by the Human Research Ethic Committee, 
Universiti Putra Malaysia (UPM/FPSK/PADS/T7-
MJKEtikaPer/F01) and the Ministry of Health Malaysia 
(NMRR-08-481-1636).
Fuhrman grading system
Two independent pathologists reviewed all the selected 
RCC slides under light microscopy. The RCC grades were 
determined using Fuhrman grading system. The grading 
was based on the nuclear size, shape and nucleoli and 
was divided into 4 grades (grade I-IV). 
Age and ethnic groups
Demographic data of RCC patients’ undergone 
nephrectomy were obtained from the histopathological 
examination request forms submitted to the Department 
of Pathology.
Immunohistochemistry staining for VEGF
The FFPE blocks that showed RCC were selected. The 
blocks sectioned at 4µm thick using a microtome. The 
tumour tissues were put on Poly-L-Lysine coated slides. 
Subsequently they were subjected to deparaffinization 
and rehydration using a series of xylene and alcohol 
solution at decreasing concentration. Antigen retrieval 
was carried out via microwave treatment at 100oC for 
20 minutes before stained with primary antibody.  The 
tissue sections were then treated with a 1:100 dilution of 
a monoclonal mouse anti-human VEGF antibody (Clone 
VG1; DAKO, Denmark). Detection was performed using 
the Dako Envision Detection system, Peroxidase/DAB+ 
(K4065; Dako). As part of a quality assurance, normal 
kidney tissue was selected as a positive control. The 
RCC cases were stained concurrently with the positive 
control tissue. The presence of cytoplasmic staining of 
the tubular cells of the kidney indicated that the positive 
control was working. The cases that showed optimum 
staining with minimum background staining were 
selected in this study. 
Scoring for VEGF
The RCC slides that were stained with VEGF antibody 
were reviewed under light microscopy. The positive 
or negative staining was determined by the presence 
or absence of cytoplasmic staining. The intensity of 
VEGF expression was scored as 0 (negative), 1+ (weak), 
2+ (moderate) or 3+ (strong). The cut off point for 
positive expression was presence 5% or more of VEGF 
expression of the tumour cells.  If the staining was weak 
or equivocal, the slides were re-evaluated; and were 
regarded as negative if an equivocal result was obtained 
again. Only cytoplasmic with or without cytoplasmic 
membrane staining was considered as positive staining.
Scoring for VEGF have been done by two qualified 
pathologists. 
Statistical analysis
The demographic distribution and VEGF expression of 
the cases were analysed using SPSS version 21. The 
spearman correlation test was used to analyse correlation 
between VEGF expressions score with grades of RCC.
RESULTS
Forty cases of histologically confirmed renal cell 
carcinoma were included into the study. The mean age 
of the patients was 56.2 years (age ranged between 16 
to 74 years). Of forty cases, there were 27 (67.5%) males 
and 13 (32.5%) females with a M: F ratio of 2.1:1. There 
were 17 (42.5%) Malays, 15 (37.5%) Chinese and 8 
(20%) Indian. Table I illustrates the demographic profile 
of RCC in the study.
VEGF immunohistochemistry
Table II shows distribution of grades and VEGF positivity. 
36 (90%) RCC were immunopositive for VEGF (Figure 
1). Among the 36 cases that were immunopositive, 
8 (16.7%) were grade 1, 20 (55.6%) grade 2, and 8 
(16.7%) grade 3. There was no grade 4 RCC case in this 
study. Spearman’s correlation test showed correlation 
coefficient -0.14 with the p value of 0.39, which is 
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insignificant. As a result, the null hypothesis not rejected 
VEGF expression is not associated with higher grades of 
renal cell carcinoma.
DISCUSSION
RCC is an adult cancer and frequently occurs in sixth to 
seventh decades. Unhealthy lifestyle such as smoking 
and diseases like obesity and hypertension which are 
common among elderly have been implicated in the 
development of RCC (18). Cancer Registry report by 
Ministry of Health Malaysia (2007) reported that the 
most affected race was Chinese and men was more 
commonly affected compared to women (4).
Expressions of VEGF antibody were mainly present on the 
cytoplasmic regions of the tumour cells and occasionally 
been expressed along the cell membranes. In this study, 
immunopositive expression was documented on the 
cytoplasmic regions with or without cell membranes 
expression. 
This study showed high expressions of VEGF in most of 
RCC cases as 90% of the RCC samples demonstrated 
Figure 1: VEGF expressions in renal cell carcinoma. A) Immunonegative (0), B) Weak immunopositive (1+), C) Moderate immunopositive (2+) 
and D) Strong immunopositive (3+). (VEGF stain, Original magnification x400)
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immunopositive results. Brown et al. and Takahashi 
et al. also reported significant expressions of VEGF in 
RCC cases; 91.7% and 90% cases respectively (19, 
20). Yang et al., suggested that high expressions of 
VEGF were interrelated with elevated activity of cancer 
development (21). VEGF helps tumour progression by 
increasing vascular permeability to plasma protein, 
induces endothelial division and migration, promotes 
endothelial cell survival by inhibiting apoptosis and 
reverses endothelial senescence (22-25). 
Cancer progression is highly related to angiogenesis 
as uncontrolled cancer cells tend to exhaust their 
current blood supply. Larger tumour size tends to 
have inadequate blood supply thus inducing hypoxic 
condition leading to upregulation of VEGF expression 
(26). This suggests that VEGF could be manipulated to be 
a useful predictive tumour marker in RCC. Nevertheless 
many studies have found that the role of VEGF as a 
predictive biomarker are not conclusive (27, 28).
VEGF positive expressions were seen in other cancers 
such as in breast, lung cancer as well as in prostate 
cancer with a promising results as a tumour marker (6, 9). 
Nonetheless, this study was unable to show any positive 
relationship between VEGF expression and RCC grades. 
Our result concurs with a study conducted by Minardi et 
al., (2005) (29). They concluded that VEGF expressions 
could not be the only parameter used to predict survival 
in RCC. To date, Fuhrman grading appears to be the 
only predictive factor of survival and mortality in RCC. 
In this study, the insignificant value obtained might be 
due to the small sample size used, a larger sample size 
might produce a different outcome.  Other factors that 
might affect our finding are sampling bias and uneven 
distribution of the grades.
CONCLUSION
This study showed high expression of VEGF in RCC 
although there was no positive correlation with 
the tumour grades. VEGF has a potential role as an 
alternative target inhibitor and prognostic marker in 
RCC as VEGF expressions are highly correlated with 
vascularity, tumour proliferation and metastasis. Further 
study with a larger sample size and even distribution of 
all grades are required to confirm its association with the 
tumour grades.
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